For qualified non-clinical research buyers, including independent researchers, educators, analysts and research teams. Not for human or veterinary use.

Research evidence guide

TB-500 and thymosin beta-4 are not interchangeable evidence terms.

A cited guide to nomenclature, direct TB-500 evidence, full-length thymosin beta-4 studies and the documentation needed to compare research materials.

Evidence snapshotThe literature covers distinct materials called TB-500, full-length thymosin beta-4 and recombinant thymosin beta-4. Molecular identity must be established before findings are compared.[1]

Compare current prices and formats.

For qualified non-clinical research buyers. Not for human or veterinary use.

Disclosure: We may earn a commission from purchases made through our links.

Start with molecular identity

A 2026 review names thymosin beta-4 and TB-500 separately and describes TB-500 as a thymosin beta-4 fragment.[1] Findings involving full-length or recombinant thymosin beta-4 therefore cannot be assigned automatically to a material marketed under the TB-500 name.

Direct TB-500 evidenceA 2026 exploratory experiment compared control, BPC-157, TB-500 and combination groups in 32 male rats, with eight animals per group and a four-week endpoint.[2]
Adjacent evidenceCell, animal and limited clinical studies also examine full-length or recombinant thymosin beta-4; these are related research records, not proof of TB-500 equivalence.[3][4]

What the direct experiment reported

In the rat tendon model, the TB-500 group had a higher maximum load to failure and lower histopathology scores than controls at four weeks.[2] This was one small, single-sex animal experiment. It cannot establish human outcomes, clinical safety or the properties of a seller product.

Evidence boundary: organism, material, sample size and endpoint matter. A rat-model result does not become a human-use claim, and a product label does not establish that the material matches a publication.

Why thymosin beta-4 studies require separate treatment

A 2025 mixed translational study investigated recombinant human thymosin beta-4—not a seller material identified only as TB-500. Its 96-participant trial reported no statistically significant overall between-group difference in infarcted area, while the authors called for further rigorous randomized studies.[3]

An earlier mechanistic study examined thymosin beta-4 in cultured endothelial cells and a Matrigel model, reporting cell-migration observations.[4] These model findings are useful for research questions but do not validate a current TB-500 lot.

Procurement essentials

  • Request the exact sequence and determine whether the material is a fragment, full-length peptide or another derivative.
  • Confirm molecular form, modifications, stated quantity and format.
  • Review lot-matched identity methods, chromatographic results and mass confirmation when available.
  • Confirm storage documentation, lot traceability, shipping eligibility and returns.
  • Keep literature records and seller-lot records separate in the procurement file.

Compare current TB-500 research formats

The options below are shown for qualified non-clinical research procurement. PRX does not represent that a seller lot is equivalent to full-length or recombinant thymosin beta-4 used in a cited study.

Sources

  1. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
  2. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats
  3. Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction
  4. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells